I Seed Brachytherapy Combined with Single-Agent Chemotherapy in the Treatment of Non-Small-Cell Lung Cancer in the Elderly: A Valuable Solution

Overview

Journal Onco Targets Ther

Publisher Dove Medical Press

Specialty Oncology

Date 2020 Oct 29

PMID 33116636

Citations 2

Authors

Tian-Hua Yue

Wei Xing

Affiliations

Soon will be listed here.

Abstract

Purpose: The aim of this study was to compare the effectiveness and safety of CT-guided I seed brachytherapy combined with single-agent chemotherapy versus combined chemotherapy in the treatment of elderly NSCLC.

Materials And Methods: We retrospectively analyzed 110 patients (64 men and 46 women; mean age=71.25±7.14 years) who were diagnosed with NSCLC without distant metastases between January 2015 and May 2020. A total of 50 patients received I brachytherapy combined with single-agent chemotherapy (group A), whereas 60 patients received combined chemotherapy (group B). The response to therapy and adverse effect were compared between groups. The local response rate was evaluated by CT. Progression-free survival (PFS) and overall survival (OS) data were obtained through clinical follow-up.

Results: All patients had been treated and were followed-up for 3-60 months. The median OS and PFS were 23.71±1.41 months (95% CI=20.95-26.47) vs 16.12±0.93 months (95% CI=14.31-17.93) (<0.05) and 15.08±0.85 months (95% CI=13.42-16.74) vs 10.03±0.53 months (95% CI=9.01-11.06) (<0.05) in group A and group B, respectively. The local response rate and clinical symptoms of patients in group A were significantly relieved when compared with group B. Severe complications were not observed in either group.

Conclusion: CT-guided I seed brachytherapy combined with single-agent chemotherapy is an effective and safe therapy and shows promising results compared to combined chemotherapy alone for NSCLC in the elderly. A randomized study will be needed to assess the superiority of this combined modality treatment.

Citing Articles

Efficacy and safety of immune checkpoint inhibitors combined with iodine-125 seed implantation in driver gene-negative non-small cell lung cancer: a retrospective cohort study.

Tao X, Liang L, Xu J, Xie L, Wen Q, Zhou X J Thorac Dis. 2025; 17(1):278-288.

PMID: 39975729 PMC: 11833590. DOI: 10.21037/jtd-24-1403.

I seed implantation for lymph node metastasis from radioactive iodine-refractory differentiated thyroid carcinoma: a study on short-term efficacy and dosimetry.

Zhang W, Hao S, Wang Z, Ding T, Zhang G Front Oncol. 2024; 14:1325987.

PMID: 38988713 PMC: 11233436. DOI: 10.3389/fonc.2024.1325987.

Recent progress in radioactive seed implantation brachytherapy of non-small cell lung cancer: a narrative review.

Wang X, Tian S, Shi H, Qin H, Zhang W, Dong Y J Thorac Dis. 2024; 16(3):2167-2176.

PMID: 38617768 PMC: 11009575. DOI: 10.21037/jtd-23-1600.

References

Majem M, Juan O, Insa A, Reguart N, Trigo J, Carcereny E . SEOM clinical guidelines for the treatment of non-small cell lung cancer (2018). Clin Transl Oncol. 2018; 21(1):3-17. PMC: 6339680. DOI: 10.1007/s12094-018-1978-1. View

Osmani L, Askin F, Gabrielson E, Li Q . Current WHO guidelines and the critical role of immunohistochemical markers in the subclassification of non-small cell lung carcinoma (NSCLC): Moving from targeted therapy to immunotherapy. Semin Cancer Biol. 2017; 52(Pt 1):103-109. PMC: 5970946. DOI: 10.1016/j.semcancer.2017.11.019. View

Xiang Z, Bai M, Li G, Zou B, Zhong Z, Gao F . Safety and efficacy of I brachytherapy for bilateral lung recurrences from hepatocellular carcinoma after resection or ablation. J Cancer Res Clin Oncol. 2019; 145(7):1907-1916. DOI: 10.1007/s00432-019-02943-x. View

Reveiz L, Rueda J, Cardona A . Palliative endobronchial brachytherapy for non-small cell lung cancer. Cochrane Database Syst Rev. 2012; 12:CD004284. PMC: 11848511. DOI: 10.1002/14651858.CD004284.pub3. View

Li W, Dan G, Jiang J, Zheng Y, Zheng X, Deng D . Repeated iodine-125 seed implantations combined with external beam radiotherapy for the treatment of locally recurrent or metastatic stage III/IV non-small cell lung cancer: a retrospective study. Radiat Oncol. 2016; 11(1):119. PMC: 5022153. DOI: 10.1186/s13014-016-0688-5. View

Buzaglo J, Gayer C, Mallick R, Charap E, Ferris A, Golant M . Understanding the experience of living with non-small-cell lung cancer (NSCLC): a qualitative study. J Community Support Oncol. 2014; 12(1):6-12. DOI: 10.12788/jcso.0010. View

Bradley J, Paulus R, Komaki R, Masters G, Blumenschein G, Schild S . Standard-dose versus high-dose conformal radiotherapy with concurrent and consolidation carboplatin plus paclitaxel with or without cetuximab for patients with stage IIIA or IIIB non-small-cell lung cancer (RTOG 0617): a randomised, two-by-two.... Lancet Oncol. 2015; 16(2):187-99. PMC: 4419359. DOI: 10.1016/S1470-2045(14)71207-0. View

Liew M, Sia J, Starmans M, Tafreshi A, Harris S, Feigen M . Comparison of toxicity and outcomes of concurrent radiotherapy with carboplatin/paclitaxel or cisplatin/etoposide in stage III non-small cell lung cancer. Cancer Med. 2014; 2(6):916-24. PMC: 3892396. DOI: 10.1002/cam4.142. View

Monk B, Tewari K, Puthawala A, Syed A, Haugen J, Burger R . Treatment of recurrent gynecologic malignancies with iodine-125 permanent interstitial irradiation. Int J Radiat Oncol Biol Phys. 2002; 52(3):806-15. DOI: 10.1016/s0360-3016(01)02728-6. View

10.

Stewart A, Parashar B, Patel M, OFarrell D, Biagioli M, Devlin P . American Brachytherapy Society consensus guidelines for thoracic brachytherapy for lung cancer. Brachytherapy. 2015; 15(1):1-11. DOI: 10.1016/j.brachy.2015.09.006. View

11.

Miller K, Siegel R, Lin C, Mariotto A, Kramer J, Rowland J . Cancer treatment and survivorship statistics, 2016. CA Cancer J Clin. 2016; 66(4):271-89. DOI: 10.3322/caac.21349. View

12.

Song J, Fan X, Zhao Z, Chen M, Chen W, Wu F . I brachytherapy of locally advanced non-small-cell lung cancer after one cycle of first-line chemotherapy: a comparison with best supportive care. Onco Targets Ther. 2017; 10:1345-1352. PMC: 5338930. DOI: 10.2147/OTT.S129903. View

13.

Zhou D, Shao L, Spitz D . Reactive oxygen species in normal and tumor stem cells. Adv Cancer Res. 2014; 122:1-67. PMC: 4207279. DOI: 10.1016/B978-0-12-420117-0.00001-3. View

14.

He X, Wang J, Li Y . Efficacy and safety of docetaxel for advanced non-small-cell lung cancer: a meta-analysis of Phase III randomized controlled trials. Onco Targets Ther. 2015; 8:2023-31. PMC: 4531008. DOI: 10.2147/OTT.S85648. View

15.

Timmerman R, McGarry R, Yiannoutsos C, Papiez L, Tudor K, Deluca J . Excessive toxicity when treating central tumors in a phase II study of stereotactic body radiation therapy for medically inoperable early-stage lung cancer. J Clin Oncol. 2006; 24(30):4833-9. DOI: 10.1200/JCO.2006.07.5937. View

16.

Huo X, Huo B, Wang H, Wang L, Cao Q, Zheng G . Implantation of computed tomography-guided Iodine-125 seeds in combination with chemotherapy for the treatment of stage III non-small cell lung cancer. J Contemp Brachytherapy. 2018; 9(6):527-534. PMC: 5808001. DOI: 10.5114/jcb.2017.72605. View

17.

Yang Y, Chen A, Ma J, Wu A, Xu F . Effects of radioactive I on apoptosis of HGC-27 gastric cancer cells. Oncol Lett. 2019; 18(5):4916-4922. PMC: 6781667. DOI: 10.3892/ol.2019.10832. View

18.

Yu X, Li J, Zhong X, He J . Combination of Iodine-125 brachytherapy and chemotherapy for locally recurrent stage III non-small cell lung cancer after concurrent chemoradiotherapy. BMC Cancer. 2015; 15:656. PMC: 4596375. DOI: 10.1186/s12885-015-1657-3. View

19.

Cardenal F, Nadal E, Jove M, Faivre-Finn C . Concurrent systemic therapy with radiotherapy for the treatment of poor-risk patients with unresectable stage III non-small-cell lung cancer: a review of the literature. Ann Oncol. 2014; 26(2):278-88. DOI: 10.1093/annonc/mdu229. View

20.

Du E, Wang L, Li C, Zhang C, Qu Y, Liu R . Analysis of immune status after iodine-125 permanent brachytherapy in prostate cancer. Onco Targets Ther. 2017; 10:2561-2567. PMC: 5438076. DOI: 10.2147/OTT.S137491. View